• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    PHARMACEUTICAL COMPOSITION FOR A HEPATITIS C VIRAL PROTEASE INHIBITOR The present invention relates to a pharmaceutical composition of a hepatitis C viral protease inhibitor that is suitable for oral administration through a liquid-filled or semi-solid capsule and methods of use of that composition to inhibit the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The liquid or semi-solid pharmaceutical composition of the present invention comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable hydrophilic lipids and surfactants.
    公开号:BR112012000287B1
    申请号:R112012000287-2
    申请日:2010-07-01
    公开日:2020-12-08
    发明作者:Feng-Jin Chen；Robert J. Schwabe
    申请人:Boehringer Ingelheim International Gmbh；
    IPC主号:
    专利说明:

    Field of the Invention
    The present invention relates generally to a pharmaceutical composition of a hepatitis C protease inhibitor, methods of using that composition to inhibit the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. Background of the Invention
    The following compound (1):
    (hereinafter "Compound (1)" or a "compound of formula (1)") is known as a selective and powerful inhibitor of HCV NS3 serine protease. Compound (1) is within the scope of the HCV inhibitor acyclic peptide series described in US patents 6,323,180 and US 7,514,557 and US 7,585,845. Compound (1) is specifically described as Compound No. 1055 in US Patent 7,585,845 and as Compound No. 1008 in US Patent 7,514,557. Compound (1) can be prepared according to the procedures found in the references cited above, which are incorporated herein by reference in their entirety. Preferred forms of Compound (1) include crystallized forms, in particular the crystalline sodium salt form, which can be prepared as described in the examples section here.
    Compound (1) can also be known through the following alternative representation of its chemical structure, which is equivalent to the structure described above:
    where B is
    L ° is MeO-; L1 is Br and Rz is

    A common problem among protease inhibitors is that these compounds are lipophilic and have low aqueous solubility. Due to the low aqueous solubility, conventional solid and liquid pharmaceutical preparations containing these inhibitors may not be absorbed by the patient in a satisfactory manner. Of the various factors that can affect the bioavailability of a drug when administered orally, (which include aqueous solubility, drug absorption through the gastrointestinal tract, dosage strength and first pass effect), aqueous solubility is often found among the factors more important. Poorly water-soluble compounds often exhibit incomplete or erratic absorption in the digestive tract, and thus produce a less than desirable response.
    Compound (1) is zwitterionic and is capable of forming salts with strong acids and bases. Attempts to identify salts of such compounds in solid forms, which would substantially improve aqueous solubility and, therefore, bioavailability, have not been successful. Thus, there is a need in the art for pharmaceutical compositions of Compound (1) having increased bioavailability.
    Methods of formulating certain lipophilic macrocyclic compounds in pharmaceutical formulations have been previously reported. For example, Cavanak, US Patent No. 4,388,307, describes the preparation of emulsified formulations of commercially available cyclosporins, and Hauer et al., US patent No. 5,342,625 and Meizner et al. NO 93/20833 describe the preparation of cyclosporine microemulsions and microemulsion preconcentrates. Komiya et al., US patent No. 5,504,068, also describes the preparation of improved topical formulations of cyclosporine.
    Examples of "self-emulsifying" formulations of lyophilic compounds include Lipari et al, NO 96/36316, which describes a self-emulsifying preconcentrate comprising a lipophilic compound, d-alpha-tocopheryl polyethylene glycol 1000 (TPGS) succinate and a lipid phase. Gao et al., US Patent No. 6,121,313 describes a selfemulsifying formulation of a piranhona protease inhibitor comprising the compound of pyranhone, a mixture of mono and diglycerides, one or more solvents and one or more surfactants, and Gar et al., US Patent No. 6,231,887 B1 describes a self-emulsifying formulation of a piranhone protease inhibitor comprising the pyranhone compound, an amine, one or more solvents and one or more surfactants. Crison et al., US Patent No. 5,993,858 describes a self-emulsifying excipient formulation comprising an emulsion that includes an oil or other lipid material, a surfactant and a hydrophilic co-surfactant.
    Patel et al. US Patent No. 6,294,192 and 6,451,339 describe compositions for the release of a hydrophobic therapeutic agent comprising a vehicle formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Aylwin et al. US Patent No. 6,652,880 describes a liquid pharmaceutical composition in which the active is dissolved in a liquid vehicle comprising a glyceride of a long chain fatty acid and a lipophilic surfactant.
    A self-emulsifying drug delivery system (SEDDS) has also been developed for certain anti-HCV compounds, as described in US patent 6,828,301 and 7,157,424 and Patent Application Publication No. 2004/0033959. However, there remains a need in the art for a pharmaceutical formulation of Compound (1) that is sufficiently optimized, stable and bioavailable. Brief Summary of the Invention
    The present invention overcomes the aforementioned problems by providing a lipid-based pharmaceutical composition of Compound (1), suitable for oral administration through a liquid-filled or semi-solid capsule. The lipid-based pharmaceutical compositions of the present invention constitute a type of self-emulsifying drug delivery system (hereinafter "SEDDS"), and they exhibit acceptable stability and bioavailability and are, therefore, particularly suitable for the therapeutic release of the Compound ( 1).
    The pharmaceutical compositions of the present invention all comprise Compound (1), or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable lipids and hydrophilic surfactants. The compositions of the present invention may optionally include one or more additional ingredients, for example, pharmaceutically acceptable soivenies, solidifying agents, antioxidants, etc., as will be discussed in more detail below. Pharmaceutical compositions are liquid or semi-solid and are preferably encapsulated in a capsule for oral administration.
    Another important aspect of the present invention involves a method of treating a hepatitis C viral infection in a mammal by administering to the mammal a therapeutically effective amount of a pharmaceutical composition of the present invention. Brief Description of Drawings
    Figure 1 shows the results of in vitro dissolution tests of three formulations according to the present invention, illustrating the percentage amount of the Na salt of Compound (1) released / dissolved as a function of time.
    Figure 2 shows the mean plasma concentrations of Compound (1) in six dogs after dosing with five different formulations of the Compound Na salt (1).
    Figure 3 shows the mean plasma concentrations of Compound (1) in three dogs after dosing with five different formulations of Compound Na salt (1). Detailed Description of the Invention
    Terms not specifically defined here should be given the meanings that would be given to them by someone skilled in the art in the light of description and context. As used in the specification, however, unless otherwise specified, the following terms have the indicated meaning and the following conventions are assigned.
    The term "about" means within 20%, preferably within 10% and most preferably within 5% of a given value or range. For example, "about 10%" means 8% to 12%, preferably 9% to 11% and more preferably 9.5% to 10.5%. When the term "about" is associated with a range of values, for example, "about X to Y%", the term "about" is intended to modify both the lower (X) and upper (Y) values of the enumerated range. For example, "about 0.1 to 10%" is equivalent to "about 0.1% to about 10%".
    All percentages listed for quantities of ingredients are not available. 'X rx / ^ ro ^ rxfi i <xio rxrvr riar / xr> <xrx-x A r * rxrYxrxrxoir * ^ xzx liou < Vi II ^ WOI ^ VUO oau | - * Cik & I iiuαio μvou Wi 11 ci vrwi i ifJuoiyciKj entire.
    The term "pharmaceutically acceptable" with respect to a substance as used here means that substance which, within the scope of medical judgment, is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation , allergic response and the like, provided with a reasonable benefit / risk ratio and effective for the desired use when the substance is used in a pharmaceutical composition.
    The term "semi-solid" means a material that is neither solid (elastic behavior) nor liquid (viscous behavior) and has the characteristics of viscosity and elasticity. Examples of semi-solid materials include highly viscous gels, ointments, creams and liquids.
    The terms "treat" or "treatment" mean the treatment of a hepatitis C viral infection in a patient, and include: (i) prevention of hepatitis C viral infection from occurring in a patient, in particular, when such a patient is predisposed such a state of disease, however, has not yet been diagnosed as having the disease; (ii) inhibition or improvement of hepatitis C viral infection, that is, preventing or delaying its development; or (iii) relief of viral infection by hepatitis C, that is, causing regression or cure of the disease state.
    The term "therapeutically effective amount" means an amount of a compound according to the invention which, when administered to a patient in need of it, is sufficient to carry out treatment of a viral infection with hepatitis C. Such amount therapeutically Effectiveness can be determined in the usual way by someone skilled in the art with respect to his own knowledge, the prior art and its description. Preferred Modalities of the Invention
    As a general embodiment of the present invention, the pharmaceutical composition comprises a compound of formula (1) or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable lipids and one or more pharmaceutically acceptable hydrophilic surfactants. In a more specific embodiment, the pharmaceutical composition consists essentially of a compound of the formula (1) or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable lipids and one or more pharmaceutically acceptable hydrophilic surfactants. Compound (1)
    Compound (1) can be used in its free form or in the form of its pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" means a salt of a compound (1) that is, within the scope of medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like , provided with a reasonable benefit / risk ratio, generally soluble or dispersive! in water or oil and effective for its intended use.
    The term includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. Lists of suitable salts are found in, for example, S. M. Birge et al., J. Pharm. Sci., 1977, 66, pp. 1 to 19 and US Patent 7,585,845. The various salts listed in US Patent 7,585,845 are incorporated herein by reference.
    A particularly preferred form of Compound (1) to be used in the composition of the present invention is the sodium salt form of Compound (1). Methods for making the crystalline sodium salt form are provided in the Examples section here. The sodium salt of Compound (1) could be crystalline, amorphous or mixtures thereof. It could also be a polymorph other than the current crystalline drug substance as described herein. The drug substance of Compound (1) can be used directly as is or it can be subjected to an appropriate process to (1) reduce the extent of drug substance particle agglomeration and / or (2) reduce the particle size distribution of the main particles of the drug substance. The process could be sieving, de-agglomeration, impact grinding, jet grinding or combinations thereof to reduce the mixing time from mass filling to encapsulation.
    The amount of the active ingredient of Compound (1) that may be present in the lipid-based system composition can vary widely or be adjusted widely depending on the intended route of administration, the potency of the particular active ingredient being used, the degree of of hepatitis C viral infection and the required concentration. In a particular embodiment, the compound of formula (1) is present in the lipid-based system in an amount of about 1% to 50% by weight, preferably about 5% to 30% by weight, more preferably about from 10% to 20% by weight. Lipid Material
    As is known in the art, an empirical parameter commonly used to characterize the relative hydrophilicity and hydrophobicity of compounds is the hydrophilic-lipophilic balance ("HLB" value). Surfactants with lower HLB values are more hydrophobic and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic and have greater solubility in aqueous solutions. Using HLB values as a rough guide, hydrophilic surfactants are generally considered to be those compounds with an HLB value greater than about 10, as well as anionic, cationic or zwiterionic compounds for which the HLB scale is not generally applicable. Similarly, hydrophobic surfactants are compounds with an HLB value less than about 10.
    Pharmaceutically acceptable lipids useful in the composition of the present invention include any lipophilic material with a hydrophilic-lipophilic balance ("HLB" value) of less than or equal to 10 (HLB <10) within limited water solubility. Examples of pharmaceutically acceptable lipids that are useful include a wide spectrum of water-immiscible materials such as, for example, fatty acids, mono, di or triglycerides of medium or long chain, esters of propylene glycine fatty acid, sorbitol fatty acid esters, water-insoluble vitamins and mixtures thereof. In a preferred embodiment, the pharmaceutically acceptable lipid is selected from. monoghcerides of caprylic and capric fatty acids, diglycerides of caprylic and capric fatty acids and mixtures thereof (eg CAPMUL® MCM from Abitech Corp.).
    The amount of lipid in the composition can vary over a wide range and the optimum amount for a particular composition will depend on the type and quantity of the other ingredients in the composition as can be determined by the skilled pharmaceutical technician. In general, however, the pharmaceutically acceptable lipid is present in an amount of about 20% to 70% by weight, more preferably in an amount of about 30% to 60% by weight or in an amount of about 40% to 50% by weight. Hydrophilic surfactant
    To facilitate self-emulsification, the composition of the present invention includes a pharmaceutically acceptable hydrophilic surfactant with an HLB value of more than or equal to 10 (HLB> 10) with good miscibility with water. Examples of pharmaceutically acceptable hydrophilic surfactants that are useful include polyethoxylated vegetable oils, polyethoxylated tocopherols, polyethoxylated sorbitol fatty acid esters (e.g., Tween 80), bile salts, lecithins and mixtures thereof. Preferred surfactants include polyethylene glycol tocopheryl succinate (Vitamin E TPGS), polyoxyl 40 hydrogenated castor oil (Cremophor RH40) and polyoxyl 35 castor oil (Cremophor EL) and mixtures thereof.
    The amount of hydrophilic surfactants in the composition can also vary over a wide range and the optimum amount for a particular composition will depend on the type and quantity of the other ingredients in the composition as determined by the skilled pharmaceutical technician. The pharmaceutically acceptable hydrophilic surfactant is preferably present in an amount of up to about 70% by weight, preferably from about 20% to 50% by weight, more preferably from 25% to 35% by weight. Hydrophilic Solvent
    The composition of the present invention may optionally also comprise a pharmaceutically accessible hydrophilic solvent to: (1) increase the solubility of the active drug substance and prevent its precipitation from the formulation, (2) reduce the mixing time of the composition. bulk liquid chilling during manufacturing for encapsulation in capsules and / or (3) increasing the aqueous dispersibility of the formulation. Examples of hydrophilic solvents that can be used include, for example, propylene glycol, polypropylene glycol, polyethylene glycol, glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, water or mixtures thereof. Preferred hydrophilic solvents include propylene glycol, polyethylene glycol (eg, PEG 400), ethanol, water and mixtures thereof.
    The amount of solvent in the composition can also vary over a wide range and the optimum amount for a particular composition will depend on the type and quantity of the other ingredients in the composition as can be easily determined by the skilled worker. In general, however, the solvent (s) are present in an amount of up to about 30% by weight, preferably up to 15% by weight. Solidification Agent
    The composition of the present invention can optionally also comprise a solidifying agent for converting the liquid formulation into a semi-solid after encapsulation in two-piece hard capsules (e.g., gelatinous hard capsules and HPMC capsules). Examples of solidifying agents that can be used include polyethylene glycols, poloxamers, polyvinylpyrrolidone, polyvinylalcohols, cellulose derivatives, polyacrylates, polymethacrylates, sugars, polyols and mixtures thereof. Specific preferred examples include high molecular weight PEGs including PEG3350, PEG6000, PEG8000, poloxamers or mixtures thereof. The inclusion of a solidifying agent is particularly useful for compositions containing propylene glycol or ethanol to reduce the activity of the gelatin plasticizer from migrating from the liquid filler into the shell of the capsule, thereby improving physical stability with respect to softening and deformation of the dosage form. On the other hand, this approach is also useful for compositions containing PEG400 to reduce the hygroscopicity of the filling and fragility of the capsule. When used in the composition, the solidifying agent is preferably present in an amount of up to about 50% by weight, preferably about 1 to 20% by weight. Optional Additional Ingredients
    If desired, the compositions according to the present invention can also include conventional pharmaceutical additives as is necessary or desirable to obtain a formulation, such as antioxidants, lubricants, disintegrants, preservatives, buffers, stabilizers, sequestrants, thickening agents , coloring agents, sweetening agents, flavoring agents, fragrances, etc. Additional additives that may be useful in the compositions of the invention are described in Llinas-Brunet et al., US patent No. 6,323,180 B1.
    In a preferred embodiment, the compositions according to the present invention also contain one or more antioxidants. Preferred antioxidants include, for example, ascorbic acid, sulfatide salts, citric acid, propyl gallate, d1-alpha-tocopherol, ascorbyl palmitate, BHT or BHA, If present, the antioxidant is generally present in an amount of about 0 , 01% to 1% by weight.
    In another preferred embodiment, the composition of the present invention may also comprise an active carbonyl (eg, aldehydes, ketones) sequestering (eg, amines including TRIS and meglumine) to reduce the crosslinking of gelatin capsules that can adversely affect the release of the dosage form formulation.
    Stabilizers that can be used can include, for example, some alkaline agents, including amines, which can raise the apparent pH of the fill formulation. Additional Preferred Modalities
    In additional embodiments, the composition of the present invention is characterized in that it does not include (or have only limited amounts of) one or more classes of materials that can typically be included in pharmaceutical formulations. In the context of the description below, the expression "substantially free of" a given material in general means that the formulation contains no more than a trace amount of the material, for example, no more than 1% by weight , preferably not more than 0.5%, even more preferably not more than 0.1% by weight.
    The composition of the present invention can be characterized by one or more of the following characteristics: (1) or substantially free of any amine compound, or contain no amine compound; (2) either substantially free of any alcohol compound, or not containing any alcohol compound; (3) either substantially free of any triglyceride compound, or containing no triglyceride; (4) either substantially free of any glyceride from a long chain fatty acid, or contain no such glyceride; (5) either substantially free of any additional surfactant compounds, or contain no additional surfactant compounds.
    A particular embodiment of the composition according to the present invention is directed to a pharmaceutical composition comprising (or consisting essentially of): (a) about 5% to 30% by weight of a compound of the formula (1) or a pharmaceutically acceptable salt thereof; (b) about 30% to 60% by weight of a pharmaceutically acceptable lipid; (c) about 20% to 50% by weight of a pharmaceutically acceptable hydrophilic surfactant; (d) optionally up to about 30% by weight of a pharmaceutically acceptable hydrophilic solvent.
    An additional particular embodiment of the composition according to the present invention is directed to a pharmaceutical composition comprising (or consisting essentially of): (a) about 10% to 20% by weight of a compound of formula (1) or a
    Wz-s lAArkni-v-irk í> d! idi 11 lαucuLiuαi I ici lie αucuαvci uv i iicoi iuu, (b) about 40% to 50% by weight of a pharmaceutically acceptable lipid; (c) about 25% to 35% by weight of a pharmaceutically acceptable hydrophilic surfactant; (d) about 5% to 15% by weight of a pharmaceutically acceptable hydrophilic solvent.
    A further particular embodiment of the composition according to the present invention is directed to a pharmaceutical composition comprising (or consisting essentially of): (a) about 5% to 30% by weight of a compound of formula (1) or a pharmaceutically acceptable salt thereof; (b) about 30% to 60% by weight of a pharmaceutically acceptable lipid selected from fatty acids, medium or long chain mono, di or triglycerides, propylene glycol fatty acid esters, sorbitol fatty acid esters, water-insoluble vitamins and mixtures thereof; (c) about 20% to 50% by weight of a pharmaceutically acceptable hydrophilic surfactant selected from polyethoxylated vegetable oils, polyethoxylated tocopherols, polyethoxylated sorbitol fatty acid esters, bile salts, lecithins and mixtures thereof ; (d) optionally up to 30% by weight of a pharmaceutically acceptable hydrophilic solvent selected from propylene glycol, polypropylene glycol, polyethylene glycol, glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, water or mixtures thereof ;
    An additional particular embodiment of the composition according to the present invention is directed to a pharmaceutical composition comprising (or consisting essentially of): (a) about 10% to 20% by weight of a compound of formula (1) such as sodium salt; (b) about 40% to 50% by weight of a pharmaceutically acceptable lipid selected from monoglycerides of caprylic and capric fatty acids; Giglicerides of caprylic and capric fatty acids and mixtures thereof; (c) about 25% to 35% by weight of a pharmaceutically acceptable hydrophilic surfactant selected from tocopherols! polyethylene glycol succinate, polyoxol 40 hydrogenated castor oil and polyoxyl 35 castor oil and mixtures thereof; (d) about 5% to 10% by weight of a pharmaceutically acceptable hydrophilic solvent selected from propylene glycol, polyethylene glycol, ethanol, water and mixtures thereof. Manufacturing and Encapsulation Method
    The composition of the present invention can be prepared in a conventional manner, for example, by a method which comprises mixing the liquid components, for example, the lipid (s), surfactant (s) and pharmaceutically soluble (s) acceptable (lo); optionally heating the obtained mixture, if necessary, to sufficiently melt one or more of the components of the mixture; add the compound of formula (1) to the resulting mixture and further mix until all or substantially all components of formula I are solubilized, for example, until the solution is visually clear. This method of preparing the composition is another aspect of the present invention.
    The resulting filling solution is then formulated in the desired dosage form, for example, capsules that include hard shell or softgel capsules (for example, hard or soft gelatin capsules), using known manufacturing technology. Examples of soft gel capsules that can be used include those described in EP 649651 B1 and US Patent 5,985321.
    In a particularly preferred embodiment, the composition of the present invention is encapsulated in soft elastic capsules, for example, soft gelatin capsule and other non-animal based soft capsules. Since the composition can be substantially free of polar solvent, it can offer the advantage of using a standard off-shelf gel composition for the capsule shell or a direct development of a new gel for the capsule shell to minimize challenges and development costs. Since a soft capsule can withstand a larger filling volume, the composition of the present invention will have the advantage of providing superior drug loading.
    It is noted that the composition of the present invention may further comprise water inherent in the drug substance, excipients (in particular surfactants and solvents that are hydrophilic in nature) and as generated during the encapsulation process. Particularly when encapsulating the filling formulation with soft gel capsules large amounts of moisture can migrate into the fill formulation from the wet gelatin tapes. It is important to remove any excess moisture from the filler composition using an appropriate drying process to avoid any precipitation and hydrolytic degradation of the drug substance and excessive softening of the capsule. Typically, the finished soft gelatin capsules of the present invention should comprise no more than 5% by weight and most preferably no more than 3% by weight of water in the fill formulation.
    One of the important discoveries regarding the compositions of the present invention is that the solubility of the sodium salt of Compound (1) increases as the temperature decreases. This unexpected property offers a unique opportunity to increase the stability of the drug product by cold storage (eg refrigeration) without the question of potential drug precipitation at the lowest temperature. As a result, the compositions of the present invention have an unexpected advantage in the development of packaging that allows a wide range of packaging materials to be used. Therapeutic Use Methods
    The compounds of formula (1) are effective as inhibitors of HCV protease, and those compounds and pharmaceutical compositions comprising these compounds are therefore useful in inhibiting HCV replication and in treating HCV infection in a mammal. Therefore, the present invention is also directed to treating a viral infection by infection in a mammal by administering to the mammal a therapeutically effective amount of a pharmaceutical composition of the present invention.
    Dosage levels of the compounds of formula (1) and various treatment regimens in monotherapy for the prevention and treatment of HCV infection are shown in US Patent 7,585,845. As the skilled person will appreciate, however, lower dosages may be possible with the compositions of the present invention depending on the level of increase in bioavailability. Combination therapy is also possible with one or more additional therapeutic or prophylactic agents as widely described by US Patent No. 7,585,845. The add-on agent (s) can be combined with the compounds of this invention to create a single dosage form or, alternatively, that additional agent (s) can be administered separately to a mammal as part of a multiple dosage form. An appropriate therapeutically effective amount of the pharmaceutical composition to be administered can be routinely determined by one of ordinary skill in the art with respect to his own knowledge, the prior art and that description.
    In order for this invention to be more widely understood, the following examples are established. These examples are for the purpose of illustrating modalities of that invention, and are not to be construed as limiting the scope of the invention in any way. Drug Product Characteristics
    The lipid-based drug delivery system of the present invention was selected due to the lipophilic nature of the sodium salt of Compound (1). Formulations of SEDDS (self-emulsifying drug delivery system) based on lipids are able to overcome the limited absorption by solubility. Since the drug substance is in solution in dosage form and is kept in solution by contact with aqueous media due to the formulation's self-leveling properties, absorption is not limited by dissolution rate.
    A liquid-filled soft gelatin capsule formulation according to the present invention has been developed for use in clinical trials. Important performance attributes include: - bioavailability (rapid release during in vitro dissolution; absorption comparable in dogs to previous powder for oral solution formulations); - stability (demonstrated chemical and physical stability of the dosage form under long-term storage conditions of ICH, 25 ° C / 60% RH); - manufacturing (batch sizes up to 25 kg feasible to withstand test requirements).
    The data is provided in the Examples section in this document demonstrating the superior stability and bioavailability characteristics of the capsule formulation of the present invention.
    The optical clarity of formulations of the present invention was observed visually and measured spectroscopically. The filler formulations were prepared according to Example 1 below (as well as corresponding vehicle and placebo formulations), and diluted to 100 times solutions in aqueous media. The absorbance of each solution was measured at 400 nm and 450 nm, using a purified water standard, and detailed results are provided in the Examples in the Examples section here. The results demonstrate absorbances of the dispersions in the range of 2.36 to 2.99 at 400 nm 0.35 to 2.96 at 450 nm. Accordingly, an additional embodiment is directed to a pharmaceutical composition according to the present invention in which, upon dilution with an aqueous solution in an aqueous solution at a composition ratio of 100: 1 by weight, the composition forms an aqueous dispersion with a absorbance of more than about 1.0 at a wavelength of about 400 nm, and preferably more than about 2.0 at a wavelength of about 400 nm. Examples
    Three different liquid filler formulations were made - uZiQctS, ivi ai 11 luα ^ ouiαuαo d 11 uαjjouiαo uc òunyci and one encapsulated in a hard shell capsule (HSC).
    Example 1 - Softgel Capsule Formulation No. 1 The composition of the liquid fill formulation:


    Two specific soft gel capsule drug product formulations were prepared according to the general Formulation No. 1 above, a 40 mg product and a 120 mg product:
    1 42.30 mg of the Na salt of Compound (1) is equivalent to 40.0 mg of the active portion. 2 126.90 mg of the Na salt of Compound (1) is equivalent to 120.0 mg of the active portion. 5 3Nitrogen is used as a processing aid and does not appear in the final product. 4 The approximate weight of the capsule shell before drying and finishing is 280 mg. The approximate weight of the capsule shell after drying and finishing is 198 mg. 10 5 The approximate weight of the capsule shell before drying and finishing is 590 mg. The approximate weight of the capsule shell after drying and capping is 404 mg.
    Example 2 - Softgel Capsule Formulation No. 2
    The composition of the liquid fill formulation:

    A specific 150 mg softgel capsule drug product formulation was prepared according to the general formula above.
    Example 3 - No. 3 Hard Shell Capsule Formulation The composition of the liquid fill formulation:


    A specific 150 mg hard shell capsule drug product formulation was prepared according to the above general formula. Preparation of Formulations 1 to 3:
    The drug substance is jet-milled to remove large aggregates so that the mixing time for making the bulk fill will be consistent and reasonably short. The target particle size distribution of the drug substance is to reduce x90 (v / v) to no more than 10 microns and x98 (v / v) to no more than 20 microns as measured by Sympatec. All excipients in the fill formulation are combined in a mixing vessel and mixed until uniform before adding the drug substance. After adding the drug substance, mixing continues until the filling solution is clear by visual inspection. A blanket of nitrogen over the filling solution is used throughout the preparation as standard practice. The filling solution is passed through a filter to remove any foreign particles. Encapsulation of the filtered bulk filler material in capsules is carried out using standard hard gelatin or soft gelatin capsule technology and process controls. Filled capsules are dried and then washed with a finishing / washing solution before packaging resulting in shiny, pharmaceutically elegant capsules.
    Example 4 - Chemical stability studies
    Stability was assessed in a prototype formulation of a capsule of superior strength (150 mg; based on sodium salt) with the same relative amounts of filler excipients and a gel formulation as Formulation No. 1 (Example 1) and which is qualitatively the same as Formulation No. 1. No significant change in test profile or impurity was noted after 12 months at 25 ° C / 60% RH or 30 ° C / 70% RH.
    Example 5 - Dissolution and Bioavailability Studies
    An in-glass dissolution method was used to evaluate Formulations 1 to 3. The results demonstrate the release of the capsule filling formulation and the dispersion of the drug substance in the lipid-based self-emulsifying drug delivery system upon contact with aqueous media. . See figure 1. The dissolution test was conducted according to the following protocol: 2 x 150 mg capsules for each formulation; conducted in 500 ml pH 4.5 acetate buffer solution per container; 100 rpm, baskets, at 37 ° C.
    In addition, the bioavailability of SEDDS formulation capsules has been demonstrated in vivo in dogs, showing absorption comparable to previous "powder-in-bottle" oral solution formulations that have been shown to result in sufficient exposure in human clinical studies. The protocol and results of these in vivo studies are provided below.
    Study of Formulation of Crossbreeding in Five Modes in Beagle Dogs Animals / Project: 6 male beagle dogs in a crossing project. There was a week of total failure I between visits 1 and 2 & visits 3 and 4. There were your weeks of total failure as viskas z and o & visits 4 and 0.
    Pre-treatment: pentagastrin at 6 μg / kg IM one hour before dosing with formulations.
    Feeding status: overnight fast (fed after 4 hours) Formulations: A - oral powder-in-bottle (PIB) phase la solution, 150 mg dose, 48 mg / mL B - oral powder-in-bottle solution ( PIB) lb / ll phase, 150 mg dose, 48 mg / ml C - SGC capsule formulation No. 1, 150 mg dose D - SGC capsule formulation No. 2, 150 mg dose E - HGC capsule formulation No. 3 , 150 mg dose
    Dosage: PIB oral solutions phases la and lb / ll were formulated with 48 mgZmL of Compound Na salt (1). The dogs were medicated to a volume of approximately 3.13 mL (150 mg dose) followed by 50 mL of water through gavage. Formulations C, D and E were formulated to contain 150 mg of Compound (1) sodium salt in each capsule. The dogs received a capsule followed by 50 mL of water through gavage.
    Blood sampling: blood samples (~ 2 ml) were taken in a pre-dose, 0.33; 0.67; 1; 1.5; two; 3; 4; 6; 8; 12; 24; 30 and 48 h post-dose. Anticoagulant: Li-Heparin Table 1: Summary of Pharmacokinetic Parameters of Compound (1) in Beagle Dogs (n = 6) after Oral Administration of Compound Na Salt (1) in Five Different Formulations3
    a Data are presented as mean (% RSD) except for tmax which is shown as mean (range). The Table includes data for all dogs regardless of emesis.
    The corresponding mean plasma concentrations of Compound (1) in all dogs after medication with five different formulations of Compound Na salt (1) (n = 6) are shown in figure 2. Table 2: Summary of Compound Pharmacokinetic Parameters ( 1) in Beagle Dogs (n = 3) after Oral Administration of Compound Na Salt (1) in Five Different Formulations3

    a Data are presented as mean (% RSD) except for tmax which is presented as mean (range). The Table excludes all data for all formulations for dogs that have vomited; 1494, 1912, 1916.
    The corresponding mean plasma concentrations of Compound (1) in the three dogs after medication with the five different formulations of the Compound Na salt (1) (n = 3) are shown in figure 3. Example 6 - Studies of optical oiareza
    The optical clarity of formulations of the present invention was observed visually and measured spectroscopically. The filler formulations were prepared according to Formulation No. 1 (Example 1), as well as corresponding vehicle and placebo formulations, and each diluted 100 times the solutions in three different aqueous media at different pH levels. The absorbance of each solution was measured immediately and after 30 minutes at 400 nm and 450 nm, using a purified water standard, and detailed results are provided below. The results demonstrate absorbances of the resulting dispersions in the range of 2.36 to 2.99 at 400 nm 0.35 to 2.96 at 450 nm.
    General Procedure:
    Add 0.1 g of formulation sample to the 20 mL Scintillation vial
    Add 9.9 mL of aqueous media to the vial
    Scattered well by manual mixing
    Measure immediately or let sit for 30 minutes
    Scattered sample before UV reading
    Transfer aliquot to 1 cm path length UV cell
    Absorbance measured as a single determination or through a range of simulated gastric fluid (SGF) simulated intestinal fluid acetate buffer (SIF) spectrophotometer Cary 50 UV-Vis software program Cary "simple reads"
    Results of optical clarity (zero time):

    Example 7 to 12 - Manufacture of Compound Na salt (1)
    Methods that can be used to prepare amorphous Compound (1) can be found in US patent 6,323,180, US patent 7,514,557 and US patent 7,585,845, which are incorporated herein by reference. Methods that can be used to prepare the sodium salt of Compound (1) can be found in US Patent Application Publication No. 2010/0093792, and in the examples set out below.
    Example 7 - Preparation of Type A of Compound (1) Compound (1) amorphous (Batch 7; 13.80 g) was added to a 1000 ml three-necked flask. Absolute ethanol (248.9 g) was added to the flask. During stirring, the contents of the flask were heated to 60 ° C / h to ~ 74 ° C. (Solids did not dissolve at 74 ° C). Water (257.4 g) was then added linearly over 4 h to the resulting slurry while stirring and maintaining the temperature at 74 ° C. After the addition of water was completed, the temperature was reduced in a linear fashion to room temperature at 8 ° C / h and then kept at room temperature for 6 hrs during stirring. The resulting solids were collected by filtration and washed with 50 ml of 1/1 (w / w) EtOH / water. The wet solids were dried in the funnel for 30 minutes by sucking N2 through the cake. (XRPD analysis in this sample indicates that the pattern is similar to the EtOH solvate). The solids were then dried at 65 to 70 ° C under vacuum (P = 25 in Hg) and a nitrogen drain for 1.5 h. The resulting solids (12.6 g; 95.5% corrected yield) were confirmed by XRPD as being Compound (1) Type A.
    Example 8 - Preparation of Compound Sodium Salt (1) - Method 1 2.1 g of amorphous sodium salt of Compound (1) and 8.90 g of acetone were added to a flask and stirred at room temperature for 3 h . The slurry was removed by filtering mother liquors and the resulting solids were dried for 20 minutes under nitrogen flow for 20 minutes. 1.51 g of crystalline sodium salt of Compound (1) as solids were collected.
    Example 9 - Preparation of Compound Sodium Salt (1) - Method 2 15.6 g of Compound Type A (1), 175 ml of acetone and 3.6 ml of water were added to a 250 ml reactor and heated at 53 ° C to dissolve the solids. 900 μl of 10.0 N NaOH was added to the reactor and the solution was seeded with Type A. The seeded solution was stirred at 53 ° C for 10 minutes. A second portion of 900 µl of 10.0 N NaOH was added and the system was stirred at 53 ° C for 30 minutes during which a slurry developed. The slurry was cooled to 19 ° C at a cooling rate of 15 ° C per hour and kept overnight at 19 ° C. The resulting slurry was filtered and the wet solids were washed with 15 ml of acetone. Dry solids for 1 h at 52 ° C under vacuum with a nitrogen flow and then expose the solids to the laboratory air for one hour. 12.1 g of Compound / <4 UA crystalline sodium salt solids were collected
    Example 10 - Preparation of Compound Sodium Salt (1) - Method 3 25.4 kg of amorphous Compound (1), 228 L of THF and 11.1 kg of 10% by weight NaOH (aq) were added to a reactor. The components were mixed at 25 ° C to dissolve all the solids. The resulting solution was filtered and the reactor and filter were washed with 23 L of THF. 180 L of solvent was removed using atmospheric distillation at 65 ° C. 195 L of MIBK was added and 166 L of solvent was removed by vacuum distillation at ~ 44 ° C. 161 L of MIBK and 0.41 kg of water were added back to the reactor and the contents were heated to 70 ° C. 255 g of Compound Na salt (1) seeds were added at 70 ° C and 1.42 L of water was added over 1.5 hours. After adding water, the slurry was kept at 70 ° C for 45 minutes and then cooled to 45 ° C in 1 h. The resulting slurry was filtered and washed with 64 L of MIBK containing ~ 0.8% by weight of water. The wet cake was dried at 55 ° C to give ~ 25 kg of crystalline sodium salt of Compound (1).
    Example 11 - Preparation of Compound Sodium Salt (1) - Method 4 2.00 g of amorphous Compound (1); 9.96 g of THF and 0.11 g of water were added to a reactor and stirred at room temperature to dissolve the solids. 0.820 ml of 21 wt% NaOEt in ethanol was added dropwise while stirring the solution to reach solution A. 15.9 g of n-BuAc and 160 ul of water were added to a second reactor and heated to 65 ° C (solution B). 2.56 g of Solution A was added to Solution B at 65 ° C and the resulting mixture was seeded with 40 mg of seeds of Compound sodium salt (1). The seeded mixture was aged at 65 ° C for 45 minutes. 2.56 g of Solution B were added to Solution A and aged for 45 minutes at four separate intervals. After the final addition and aging, the slurry was cooled to 50 ° C for 1 hour and filtered. The wet cake was washed with 6 ml of n-BuAc containing 0.5% water by weight. The final solids were dried at 50 ° C under vacuum using a nitrogen purge. The solids from the crystalline sodium salt of Compound (1) were collected. Example 12 - Preparation of Compound Sodium Salt (1) - Method 5
    At room temperature, a solution of sodium ethoxide in ethanol (21% by weight; 3.06 ml) was added to a solution of Compound (1) (745 g) in THF (2000 ml) and water (76.5 ml) ) during shaking. After stirring for 10 minutes, the mixture was filtered and the filter was washed with THF (8 ml). The resulting solution was heated to 65 ° C and treated with filtered butyl acetate (6640 ml, optionally preheated to 65 ° C) within 30 minutes. Seeding crystals (0.50 g) were added and the mixture was stirred at 65 ° C for 2 hours, while crystallization starts after about 30 minutes. The suspension was cooled to 50 ° C within 1 hour and stirred at that temperature for another hour. The title compound was isolated by filtration, washed with filtered butyl acetate (765 ml, optionally preheated to 50 ° C) and dried at 65 ° C for about 16 h giving crystalline sodium salt of Compound (1) ( ~ 725 g).
    权利要求:
    Claims (12)
    [0001]
    1. Liquid pharmaceutical composition, characterized by the fact that it comprises: (a) a compound of the formula (1):
    [0002]
    2. Pharmaceutical composition according to claim 1, characterized by the fact that the compound of formula (1) is present as the sodium salt.
    [0003]
    Pharmaceutical composition according to claim 1 or 2, characterized in that the compound of formula (1), or a pharmaceutically acceptable salt thereof, is present in an amount of 1 to 50% by weight.
    [0004]
    Pharmaceutical composition according to any one of claims 1 to 3, characterized in that the pharmaceutically acceptable lipid is present in an amount of about 20% to 70% by weight.
    [0005]
    Pharmaceutical composition according to any one of claims 1 to 4, characterized by the fact that the pharmaceutically acceptable lipid is selected from: medium or long chain fatty acids, mono-, di- or triglycerides , propylene glycol fatty acid esters, sorbitol fatty acid esters, water-insoluble vitamins, and mixtures thereof.
    [0006]
    Pharmaceutical composition according to any one of claims 1 to 5, characterized in that the pharmaceutically acceptable hydrophilic surfactant is present in an amount of up to 70% by weight.
    [0007]
    Pharmaceutical composition according to any one of claims 1 to 6, characterized in that the pharmaceutically acceptable hydrophilic surfactant is selected from polyoxylated vegetable oils, polyethoxylated tocopherols, polyoxylated sorbitol fatty acid esters, bile salts, lecithins, and mixtures thereof.
    [0008]
    Pharmaceutical composition according to any one of claims 1 to 7, characterized in that it further comprises a pharmaceutically acceptable hydrophilic solvent.
    [0009]
    Pharmaceutical composition according to claim 8, characterized in that the pharmaceutically acceptable hydrophilic solvent is selected from propylene glycol, polypropylene glycol, polyethylene glycol, glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide , water, or mixtures thereof.
    [0010]
    Pharmaceutical composition according to claim 8 or 9, characterized in that the pharmaceutically acceptable hydrophilic solvent is present in an amount of up to 30% by weight.
    [0011]
    Pharmaceutical composition according to any one of claims 1 to 10, characterized in that upon dilution with an aqueous solution in an aqueous solution to composition ratio of 100: 1 by weight, the composition forms an aqueous dispersion having a absorbance of more than about 1.0 at a wavelength of about 400 nm.
    [0012]
    Pharmaceutical composition according to any one of claims 1 to 11, characterized in that it comprises: (A) (a) from 5% to 30% by weight of a compound of formula (I), or a pharmaceutically salt acceptable of the same; (b) from 30% to 60% by weight of a pharmaceutically acceptable lipid; (c) from 20% to 50% by weight of a pharmaceutically acceptable hydrophilic surfactant; (d) optionally, up to 30% by weight of a pharmaceutically acceptable hydrophilic solvent; or (B) (a) from 10% to 20% by weight of a compound of formula (I), or a pharmaceutically acceptable salt thereof; (b) 40% to 50% by weight of a pharmaceutically acceptable lipid; (c) from 25% to 35% by weight of a pharmaceutically acceptable hydrophilic surfactant; (d) from 5% to 15% by weight of a pharmaceutically acceptable hydrophilic solvent; or (C) (a) from 5% to 30% by weight of a compound of formula (I), or a pharmaceutically acceptable salt thereof; (b) 30% to 60% by weight of a pharmaceutically acceptable lipid selected from fatty acids, mono-, di- or triglycerides of medium or long chain, esters of propylene glycol fatty acid, esters of sorbitol fatty acid, water-insoluble vitamins and mixtures thereof; (c) from 20% to 50% by weight of a pharmaceutically acceptable hydrophilic surfactant selected from polyethoxylated vegetable oils, polyethoxylated tocopherols, polyethoxylated sorbitol fatty acid esters, bile salts, lecithins and mixtures thereof; (d) optionally, up to 30% by weight of a pharmaceutically acceptable hydrophilic solvent selected from propylene glycol, polypropylene glycol, polyethylene glycol, glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, water, or mixtures of the same; 5 or (D) (a) from 10% to 20% by weight of a compound of formula (I), as the sodium salt form; (b) 40% to 50% by weight of a pharmaceutically acceptable lipid selected from monoglycerides of caprylic and capric acids; diglycerides of caprylic and capric fatty acids and mixtures thereof; (c) from 25% to 35% by weight of a pharmaceutically acceptable hydrophilic surfactant selected from tocopheryl succinate 15 polyethylene glycol, hydrogenated castor oil polyoxyl 40 and castor oil polyoxyl 35 and mixtures thereof; (d) from 5% to 10% by weight of a pharmaceutically acceptable hydrophilic solvent selected from propylene glycol, polyethylene glycol, ethanol, water, and mixtures thereof.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012000287B1|2020-12-08|pharmaceutical composition for a hepatitis c viral protease inhibitor
    ES2831037T3|2021-06-07|Oral self-emulsifying pharmaceutical composition of hydrophilic drugs and method of preparation
    ES2276045T3|2007-06-16|PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C VIRAL PROTEASE INHIBITORS.
    CA2726267C|2017-10-31|Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
    BR112013000802B1|2021-08-31|Solid dispersion form of rifaximin, microgranule comprising said form, pharmaceutical composition comprising said microgranule and processes for producing a solid dispersion of rifaximin
    AU2009321745B2|2016-06-23|Oral dosage forms of bendamustine
    ES2690257T3|2018-11-20|Oral dosage forms of bendamustine
    BRPI0715423A2|2013-07-02|formulations for benzimidazolyl pyridyl ethers
    WO2003017986A1|2003-03-06|Compositions containing itraconazole and their preparation methods
    TWI660730B|2019-06-01|Pharmaceutical composition including dutasteride and capsule formulation comprising the same
    MX2009000145A|2009-01-23|Ibuprofen-containing liquid filled hard capsules.
    BR112020004663A2|2020-09-15|pharmaceutical composition
    ES2325373T3|2009-09-02|PHARMACEUTICAL COMPOSITION INTENDED FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF PIRAZOL-3-CARBOXAMIDA.
    AU2015227503A1|2015-10-08|Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
    EP3854384A1|2021-07-28|Pharmaceutical formulation comprising abiraterone acetate
    KR20030074822A|2003-09-19|Pharmaceutical composition
    WO2002013789A1|2002-02-21|Pharmaceutical composition containing 1&#39;-[4-[1-|-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1|,4&#39;-piperidine]
    同族专利:
    公开号 | 公开日
    CO6480980A2|2012-07-16|
    HRP20140445T1|2014-06-20|
    ES2464367T3|2014-06-02|
    PE20120322A1|2012-04-14|
    CN102470103B|2016-09-07|
    IL216098D0|2012-01-31|
    BR112012000287A2|2016-02-23|
    EA201200096A1|2012-08-30|
    CL2012000054A1|2012-10-12|
    KR101685941B1|2016-12-13|
    US9034831B2|2015-05-19|
    NZ596928A|2013-05-31|
    EP2451438A2|2012-05-16|
    IL216098A|2016-02-29|
    ECSP12011624A|2012-02-29|
    WO2011005646A2|2011-01-13|
    SI2451438T1|2014-04-30|
    BR112012000287B8|2021-05-25|
    CN102470103A|2012-05-23|
    TW201114766A|2011-05-01|
    UA104195C2|2014-01-10|
    US20110160149A1|2011-06-30|
    JP2012532192A|2012-12-13|
    EP2451438B8|2014-04-09|
    EP2451438B1|2014-02-26|
    UY32760A|2011-02-28|
    WO2011005646A3|2011-12-22|
    PL2451438T3|2014-07-31|
    SG177569A1|2012-03-29|
    AU2010270783B2|2013-06-27|
    AP2011005979A0|2011-12-31|
    ME01718B|2014-09-20|
    MY154683A|2015-07-15|
    PT2451438E|2014-03-26|
    TWI490216B|2015-07-01|
    AR077393A1|2011-08-24|
    CA2767692C|2017-03-07|
    AU2010270783A1|2011-12-15|
    KR20120059481A|2012-06-08|
    RS53209B|2014-06-30|
    CA2767692A1|2011-01-13|
    MA33491B1|2012-08-01|
    TN2012000009A1|2013-09-19|
    DK2451438T3|2014-03-10|
    EA023433B1|2016-06-30|
    MX2011013824A|2012-01-30|
    JP5607736B2|2014-10-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FI65914C|1978-03-07|1984-08-10|Sandoz Ag|FRAMEWORK FOR PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE A|
    US5342625A|1988-09-16|1994-08-30|Sandoz Ltd.|Pharmaceutical compositions comprising cyclosporins|
    IL102236D0|1991-06-27|1993-01-14|Ltt Inst Co Ltd|Topical preparations containing cyclosporin|
    US5329976A|1991-12-09|1994-07-19|Habley Medical Technology Corporation|Syringe-filling and medication mixing dispenser|
    GB9208712D0|1992-04-22|1992-06-10|Sandoz Ltd|Pharmaceutical compositions containing cyclosporin derivates|
    SI0649651T1|1993-09-28|2001-02-28|Scherer Gmbh R P|Soft gelatin capsule manufacture|
    EP0825849A1|1995-05-19|1998-03-04|Abbott Laboratories|Self-emulsifying formulations of lipophilic drugs|
    US5993858A|1996-06-14|1999-11-30|Port Systems L.L.C.|Method and formulation for increasing the bioavailability of poorly water-soluble drugs|
    EP0989851B1|1997-07-29|2002-10-02|PHARMACIA &amp; UPJOHN COMPANY|Self-emulsifying formulation for acidic lipophilic compounds|
    SK284511B6|1997-07-29|2005-05-05|Pharmacia & Upjohn Company|Self-emulsifying formulations for lipophilic compounds|
    BR9810866B1|1997-07-29|2010-07-13|pharmaceutical composition in a self-emulsifying formulation form for lipophilic compounds.|
    US6323180B1|1998-08-10|2001-11-27|Boehringer Ingelheim Ltd|Hepatitis C inhibitor tri-peptides|
    US6294192B1|1999-02-26|2001-09-25|Lipocine, Inc.|Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents|
    US6652880B1|1999-04-01|2003-11-25|R.P. Scherer Technologies, Inc.|Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants|
    SE0000773D0|2000-03-08|2000-03-08|Astrazeneca Ab|New formulation|
    GB0008785D0|2000-04-10|2000-05-31|Novartis Ag|Organic compounds|
    AU2002351169B2|2001-11-26|2007-09-20|Intas Pharmaceuticals Limited|Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions|
    US6828301B2|2002-02-07|2004-12-07|Boehringer Ingelheim International Gmbh|Pharmaceutical compositions for hepatitis C viral protease inhibitors|
    CZ294371B6|2002-06-10|2004-12-15|Pliva - Lachema, A. S.|Stabilized pharmaceutical composition based on polyoxyethylated castor oil and process for preparing thereof|
    US20040033959A1|2002-07-19|2004-02-19|Boehringer Ingelheim Pharmaceuticals, Inc.|Pharmaceutical compositions for hepatitis C viral protease inhibitors|
    US20050075279A1|2002-10-25|2005-04-07|Boehringer Ingelheim International Gmbh|Macrocyclic peptides active against the hepatitis C virus|
    UY28240A1|2003-03-27|2004-11-08|Boehringer Ingelheim Pharma|CRYSTAL PHASES OF A POWERFUL HCV INHIBITOR|
    JP2006522017A|2003-04-02|2006-09-28|ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング|Pharmaceutical composition for hepatitis C virus protease inhibitor|
    AU2004240704B9|2003-05-21|2009-10-22|Boehringer Ingelheim International Gmbh|Hepatitis C inhibitor compounds|
    PE20050431A1|2003-09-22|2005-07-19|Boehringer Ingelheim Int|MACROCYCLIC PEPTIDES ACTIVE AGAINST HEPATITIS C VIRUS|
    ES2338666T3|2004-03-15|2010-05-11|Boehringer Ingelheim International Gmbh|PROCEDURE FOR THE PREPARATION OF APPROPRIATE MACROCICLIC DIPEPTIDES FOR THE TREATMENT OF VIRIC INFECTION OF HEPATITIS C.|
    AP2006003763A0|2004-03-30|2006-10-31|Intermune Inc|Macrocyclic compounds as inhibitors of viral replication|
    WO2005116054A1|2004-05-25|2005-12-08|Boehringer Ingelheim International, Gmbh|Process for preparing acyclic hcv protease inhibitors|
    US20060276406A1|2005-06-02|2006-12-07|Schering Corporation|Methods of treating hepatitis C virus|
    RU2490272C2|2008-02-04|2013-08-20|Айденикс Фармасьютикалз, Инк.|Macrocyclic serine protease inhibitors|
    MY153093A|2008-09-16|2014-12-31|Boehringer Ingelheim Int|Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor|
    CN102223875A|2008-11-21|2011-10-19|贝林格尔.英格海姆国际有限公司|Pharmaceutical composition of a potent hcv inhibitor for oral administration|
    CN102470103B|2009-07-07|2016-09-07|贝林格尔.英格海姆国际有限公司|Pharmaceutical composition as hcv protease inhibitors|CN102159245B|2008-09-17|2013-07-24|贝林格尔.英格海姆国际有限公司|Combination of hcv ns3 protease inhibitor with interferon and ribavirin|
    CN102470103B|2009-07-07|2016-09-07|贝林格尔.英格海姆国际有限公司|Pharmaceutical composition as hcv protease inhibitors|
    EP2493470A1|2009-10-30|2012-09-05|Boehringer Ingelheim International GmbH|Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin|
    CN103228278A|2010-09-30|2013-07-31|贝林格尔.英格海姆国际有限公司|Combination therapy for treating hcv infection|
    US8957203B2|2011-05-05|2015-02-17|Bristol-Myers Squibb Company|Hepatitis C virus inhibitors|
    US8691757B2|2011-06-15|2014-04-08|Bristol-Myers Squibb Company|Hepatitis C virus inhibitors|
    US8466159B2|2011-10-21|2013-06-18|Abbvie Inc.|Methods for treating HCV|
    PT107924A|2011-10-21|2014-12-03|Abbvie Inc|TREATMENT OF AAD COMBINATIONFOR USE IN HCV TREATMENT|
    US8492386B2|2011-10-21|2013-07-23|Abbvie Inc.|Methods for treating HCV|
    DE202012012956U1|2011-10-21|2014-10-16|Abbvie Inc.|A combination of at least two direct-acting antiviral agents for use in the treatment of HCV, comprising ribavirin but not interferon|
    CN104244926A|2012-01-12|2014-12-24|勃林格殷格翰国际有限公司|Stabilized pharmaceutical formulations of a potent HCV inhibitor|
    JP2015509980A|2012-03-14|2015-04-02|ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング|Combination therapy to treat HCV infection in a population of HCV-HIV co-infected patients|
    WO2013147750A1|2012-03-27|2013-10-03|Boehringer Ingelheim International Gmbh|Oral combination therapy for treating hcv infection in specific patient sub-population|
    WO2013147749A1|2012-03-27|2013-10-03|Boehringer Ingelheim International Gmbh|Oral combination therapy for treating hcv infection in specific patient subgenotype populations|
    JP2015512900A|2012-03-28|2015-04-30|ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング|Combination therapy to treat HCV infection in a special patient genotype subpopulation|
    PT2909205T|2012-10-19|2017-02-06|Bristol-Myers Squibb Company|9-methyl substituted hexadecahydrocyclopropapyrrolodiazacyclopentadecinyl carbamate derivatives as non-structural 3protease inhibitors for the treatment of hepatitis c virus infections|
    EP2914598B1|2012-11-02|2017-10-18|Bristol-Myers Squibb Company|Hepatitis c virus inhibitors|
    US9643999B2|2012-11-02|2017-05-09|Bristol-Myers Squibb Company|Hepatitis C virus inhibitors|
    EP2914613B1|2012-11-02|2017-11-22|Bristol-Myers Squibb Company|Hepatitis c virus inhibitors|
    US9409943B2|2012-11-05|2016-08-09|Bristol-Myers Squibb Company|Hepatitis C virus inhibitors|
    CN105164148A|2013-03-07|2015-12-16|百时美施贵宝公司|Hepatitis c virus inhibitors|
    WO2014138374A1|2013-03-08|2014-09-12|Boehringer Ingelheim International Gmbh|Oral combination therapy for treating hcv infection in specific patient sub-population|
    EA032322B1|2013-03-15|2019-05-31|Бёрингер Ингельхайм Интернациональ Гмбх|Solid oral dosage formulation of hcv inhibitor in the amorphous state|
    EP2899207A1|2014-01-28|2015-07-29|Amikana.Biologics|New method for testing HCV protease inhibition|
    CA3022119A1|2016-04-28|2017-11-02|Emory University|Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto|
    法律状态:
    2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2019-05-28| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
    2020-04-07| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2020-10-27| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2020-12-08| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
    2021-05-25| B16C| Correction of notification of the grant|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
    优先权:
    申请号 | 申请日 | 专利标题
    US22350709P| true| 2009-07-07|2009-07-07|
    US61/223,507|2009-07-07|
    PCT/US2010/040734|WO2011005646A2|2009-07-07|2010-07-01|Pharmaceutical composition for a hepatitis c viral protease inhibitor|
    [返回顶部]